Retrospective evaluation of Dysport™ and BOTOX drug utilization in the management of patients with cervical dystonia or blepharospasm

被引：0

作者：

Magar, R

Marchetti, A

Ahmed, F

Ferguson, I

机构：

[1] Thomson Phys World, Secaucus, NJ USA

[2] Hull Royal Infirm, Kingston Upon Hull HU3 2JZ, N Humberside, England

[3] Frenchay Hosp, Bristol BS16 1LE, Avon, England

来源：

VALUE IN HEALTH | 2002年 / 5卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)61354-X

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：510 / 510

页数：1

共 50 条

[31] Prevalence of Blepharospasm and Apraxia of Eyelid Opening in Patients with Parkinsonism, Cervical Dystonia and Essential Tremor
Kabir, Ashish
Rana, Abdul
Khondker, Sumaiya
NEUROLOGY, 2013, 80
[32] Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport®)
Simonetta-Moreau, M.
Picaut, P.
Volteau, M.
Poewe, W.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (06) : 943 - +
[33] The ultrasound image of the nuclei raphes changes in the group of depressed patients with cervical dystonia and blepharospasm
Krzak-Kubica, A. K.
Gawryluk, J. G.
Doregowska, M. D.
Plinta, K. P.
Rudzinska-Bar, M. R.
MOVEMENT DISORDERS, 2019, 34 : S532 - S533
[34] Prevalence of Blepharospasm and Apraxia of Eyelid Opening in Patients with Parkinsonism, Cervical Dystonia and Essential Tremor
Rana, Abdul-Qayyum
Kabir, Ashish
Dogu, Okan
Patel, Ami
Khondker, Sumaiya
EUROPEAN NEUROLOGY, 2012, 68 (05) : 318 - 321
[35] HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH CERVICAL DYSTONIA
Hull, M.
Anupindi, R.
He, J.
Danchenko, N.
DeKoven, M.
Bouchard, J.
VALUE IN HEALTH, 2022, 25 (01) : S106 - S106
[36] A retrospective drug utilization evaluation of vancomycin usage in paediatric patients
Hing, WC
Bek, SJ
Lin, RTP
Li, SC
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2004, 29 (04) : 359 - 365
[37] The effects of converting to Dysport from other botulinum toxin type A formulations for treating cervical dystonia patients
Samotus, O.
Jog, M.
MOVEMENT DISORDERS, 2022, 37 : S263 - S263
[38] Retrospective cross-over evaluation of two botulinum toxin type A preparations (Botox® and Dysport®) in the treatment of upper limb spasticity
Parman, Y.
Hanagasi, H.
Topcular, B.
MOVEMENT DISORDERS, 2007, 22 : S277 - S277
[39] Retrospective cross-over evaluation of two botulinum toxin type A preparations (Botox® and Dysport®) in the treatment of lower limb spasticity
Parman, Y.
Hanagasi, H.
Topcular, B.
MOVEMENT DISORDERS, 2007, 22 : S279 - S279
[40] Botulinum toxin in the management of pain in patients with cervical dystonia
Relja, M.
Korsiae, M.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 142 - 142

← 1 2 3 4 5 →